DBT (dihydrolipoamide branched chain transacylase E2) Blocking Peptide (the N terminal of protein) (100ug)

This is a synthetic peptide designed for use in combination with anti-DBT antibody (Catalogue #: ARP51995_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Prices direct from Aviva Systems Biology Incorporated

Quick response times

Exclusive Absave savings/discounts

SPECIFICATIONS

Size

100 ug

Format

Lyophilized powder

Presku

AAP51995

Target

The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO2. It contains multiple copies of three enzymatic components: branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3).The branched-chain alpha-keto acid dehydrogenase complex (BCKD) is an inner-mitochondrial enzyme complex involved in the breakdown of the branched-chain amino acids isoleucine, leucine, and valine. The BCKD complex is thought to be composed of a core of 24 transacylase (E2) subunits, and associated decarboxylase (E1), dehydrogenase (E3), and regulatory subunits. This gene encodes the transacylase (E2) subunit. Mutations in this gene result in maple syrup urine disease, type 2. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.

Weight

46kDa

Gene Id

1629

Alternative Names

BCATE2; E2; E2B; MGC9061